Stock events for Nuvectis Pharma, Inc. (NVCT)
Over the past six months, Nuvectis Pharma's stock price has fluctuated, increasing by 19.9% year-to-date and 37.38% over the last 12 months. Key events include reporting 2025 financial results and NXP900 development updates in February 2026, initiating a Phase 1b study of NXP900 with osimertinib for EGFRmut+ NSCLC patients in December 2025, exceeding Q3 earnings estimates in November 2025, presenting NXP900 poster highlights at a conference in October 2025, and providing a final clinical data update from the NXP800 Phase 1b study and reporting the completion of the NXP900 Phase 1a dose escalation study in July 2025.
Demand Seasonality affecting Nuvectis Pharma, Inc.’s stock price
As a clinical-stage biopharmaceutical company, Nuvectis Pharma, Inc. is primarily focused on research and development, so traditional demand seasonality is not applicable. The demand for its drug candidates is driven by clinical trial progress, regulatory milestones, and the unmet medical needs they address.
Overview of Nuvectis Pharma, Inc.’s business
Nuvectis Pharma, Inc. (NVCT) is a clinical-stage biopharmaceutical company focused on developing precision medicines for oncology. Their pipeline includes NXP900, a c-Src and YES1 kinase inhibitor in Phase 1b trials for solid tumors and NSCLC, and NXP800, a GCN2 activator with completed Phase 1b trials for ovarian cancer, with potential opportunities being explored in other cancer types.
NVCT’s Geographic footprint
Nuvectis Pharma, Inc. is headquartered in Fort Lee, New Jersey, United States. Further details about its operational or market geographic footprint are not available in the provided information.
NVCT Corporate Image Assessment
Nuvectis Pharma generally holds a positive outlook due to its advancements in clinical development and plans for expansion. Analysts have given Nuvectis Pharma a consensus rating of "Moderate Buy" or "Strong Buy". The company's lead product, NXP900, has shown encouraging initial safety signals in clinical trials, which contributes to this positive sentiment. Events that have positively affected its reputation include the successful completion of the NXP900 Phase 1a dose escalation study, initiation of the NXP900 Phase 1b study, positive pharmacokinetic study results for NXP900, presentations of clinical data at scientific conferences, and recent fundraising efforts.
Ownership
Nuvectis Pharma, Inc. has a mixed ownership structure. Approximately 13.98% of the company's stock is owned by institutional investors, 42.07% by insiders, and 43.95% by public companies and individual investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Iridian Asset Management Llc/ct. Key individual owners (insiders) include Ronald Bentsur (CEO), Charles Marlio, Enrique Poradosu, and Shay Shemesh.
